SCHEMBL2331735

SCHEMBL2331735

CCOC(=O)c1ccccc1NC(=O)C1c2ccccc2C(=O)N(CCOC)C1c1cccs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.48
ALDH1A1 P00352 8/20 0.47
KDM4E B2RXH2 5/20 0.47
HTT P42858 2/20 0.47
MAPT P10636 1/20 0.47
NPSR1 Q6W5P4 5/20 0.45
GAA P10253 1/20 0.45
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 6/20 0.42
HPGD P15428 4/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 4/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2336023 0.90 CYP2C9 (0.43) TSHRALDH1A1KDM4EHTTMAPT
SCHEMBL2330733 0.89 ALDH1A1 (0.49) TSHRALDH1A1KDM4EHTTMAPT
SCHEMBL2334371 0.85 ALDH1A1 (0.53) TSHRALDH1A1KDM4EHTTMAPT
SCHEMBL2335428 0.85 ALDH1A1 (0.51) TSHRALDH1A1KDM4EHTTMAPT
SCHEMBL2377689 0.85 ALDH1A1 (0.51) TSHRALDH1A1KDM4EHTTMAPT
SCHEMBL2331595 0.85 CYP2C9 (0.49) TSHRALDH1A1KDM4EHTTMAPT
SCHEMBL2339975 0.84 ALDH1A1 (0.45) TSHRALDH1A1KDM4EHTTMAPT
SCHEMBL2331641 0.83 ALDH1A1 (0.54) TSHRALDH1A1KDM4EHTTMAPT
SCHEMBL2380098 0.83 KDM4E (0.49) TSHRALDH1A1KDM4EHTTMAPT
SCHEMBL2337616 0.83 CYP2C9 (0.53) TSHRALDH1A1KDM4EHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-09-15 US disclosed
EP-2358682-A2 ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2011-08-24 EP disclosed
WO-2010055164-A2 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION MAVS, IRF3, EIF2AK2 TSHR 4780/4885ALDH1A1 2613/4885KDM4E 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.